Lung Cancer

Karen Lee discusses the managment of immune-related adverse events in patients who are receiving immunotherapy treatments.

Bonnie J. Addario Lung Cancer Foundation and American Lung Associate have teamed up to create a lung Cancer Registry to connect patients with lung cancer with opportunities to support research and engage with others in the community.

Dr. Puneeth Iyengar expresses the importance of nutrition and hydration for patients with stage III lung cancer.

Molly Freeman, CNP, discusses the aftercare that goes into treating patients with lung cancer who have undergone stereotactic body radiation therapy (SBRT).

Survival in patients with lung cancer could be worse when those patients suffer depression symptoms.

Dr. Puneeth Iyengar discusses the use of a hypofractioned course of radiation therapy for patients with stage 3 NSCLC instead of a combination of chemotherapy and radiation.

Pembrolizumab gains an FDA approval for frontline therapy of non-small cell lung cancer (NSCLC).

Immunotherapy agent atezolizumab approved by FDA for treatment of NSCLC.

Phase III trial results indicate that pembrolizimab reduced risk of death by 40% and improved PFS by 4.3 months for advanced NSCLC.

Immunotherapy is changing the cancer treatment game as therapies continue to be approved for more and more tumor types. This creates more responsibilities for oncology nurses.

Melisa Wong lays out the findings of a study she did looking at the age of patients with recurrent lung cancer and the likelihood they were to receive active treatment.

Morganna Freeman, DO, FCAP, from The Angeles Clinic and Research Institute gives advice on how to help a patient who is dealing with the stigma associated with melanoma, or other cancers.

Using mobile apps and other new technologies, clinicians can better monitor and help their patients.

Oncology nurses are an important resource for patients with cancer when dealing with adverse effects that can be disruptive to quality of life.

Patients with newly diagnosed incurable lung and GI cancer saw benefits from early palliative care services.

Researchers analyzed Bing.com search logs to identify those recently diagnosed with pancreatic cancer. Through symptom patterns expressed as searches, they were able to identify 5% to 15% of pancreatic cancer cases.

Robert Pirka, MD, Medical University of Vienna, discusses the role that nurses can play in making patients feel more comfortable about enrolling in a lung cancer clinical trial.

Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology, Aging Research T32 Fellow, University of California San Francisco Geriatrics, discusses the impact that comorbidities have on the treatment for lung cancer.

Jennifer Temel, MD, director of the Cancer Outcomes Research Program at Massachusetts General Hospital, discusses the benefits that palliative care can have not only on patients, but on their caregivers as well.

Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology at the University of California San Francisco, discusses differences among age groups in the treatment of non–small cell lung cancer (NSCLC).

Researchers in France have found that patients with lung cancer who used a web-based app to report and track their symptoms achieved impressive gains in survival compared with individuals who were followed using standard protocols.

Melisa Wong, MD, discusses an analysis of age and comorbidity on treatment of non-small cell lung cancer recurrence. Wong presented this analysis at the 2016 ASCO Annual Meeting.

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

The FDA is getting praise from oncology groups for its landmark decision to regulate electronic cigarettes, cigars, hookah tobacco, pipe tobacco, and other electronic nicotine delivery systems (ENDS).

The FDA has approved afatinib (Gilotrif) for the treatment of patients with advanced squamous cell non–small cell lung cancer (NSCLC) following progression on platinum-based chemotherapy.

Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).